Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kagawa Hirokazu, Urabe Fumihiko, Kiuchi Yuria, Katsumi Kota, Yamaguchi Ryotaro, Suhara Yushi, Yoshihara Kentaro, Goto Yuma, Sadakane Ibuki, Yata Yuji, Saito Shun, Kurawaki Shiro, Ajisaka Shino, Miyajima Keiichiro, Takahashi Kazuhiro, Iwatani Kosuke, Imai Yu, Sakanaka Keigo, Nakazono Minoru, Kurauchi Takashi, Kayano Sotaro, Onuma Hajime, Aikawa Koichi, Yanagisawa Takafumi, Tashiro Kojiro, Tsuzuki Shunsuke, Furuta Akira, Miki Jun, Kimura Takahiro, JIKEI-YAYOI Collaborative Group
Аннотация
METHODS: We retrospectively analyzed 895 patients who underwent nephroureterectomy to treat UTUC. The patients were divided into two groups: grade pT3-4 and/or pN + without neoadjuvant chemotherapy (NAC) or grade ypT2-4 and/or ypN + on NAC (adjuvant immunotherapy candidates) and others (not candidates for adjuvant immunotherapy). Kaplan-Meier curves were drawn to assess the oncological outcomes, including recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). Cox proportional hazards models were used to identify significant prognostic factors for oncological outcomes.
RESULTS: The Kaplan-Meier curves revealed notably inferior RFS, CSS, and OS of patients who were candidates for adjuvant immunotherapy. Multivariate analysis revealed that pathological T and N grade and lymphovascular invasion (LVI) status were independent risk factors for poor RFS, CSS, and OS.
CONCLUSION: In total, 44.8% of patients were candidates for adjuvant immunotherapy. In addition to pathological T and N status, LVI was a significant predictor of survival, and may thus play a pivotal role in the selection of patients eligible for adjuvant immunotherapy.